other

Updated:

Crown Bioscience

Crown Bioscience is a contract research organization specializing in preclinical oncology and immuno-oncology models for biotech and pharma companies globally.

Crown Bioscience

Advance translational oncology with Crown Bioscience, a full-service CRO delivering comprehensive preclinical and oncology CRO services worldwide.

General information

Firm type

other

Location

Region

North America

Country

United States

City

Santa Clara

Corporate office

Santa Clara, CA, United States

Additional offices

San Diego, CA, United States · Frederick, MD, United States · Kannapolis, NC, United States · Osgathorpe, Loughborough, United Kingdom · Leiden, Netherlands · Hamburg, Germany · Beijing, China · Shanghai, China · Suzhou, China · Taicang, China · Tokyo, Japan · Suwon, South Korea · Hyderabad, India · Singapore

Sector focus

Healthcare Services

Frequently asked questions

Which services does Crown Bioscience provide?

Crown Bioscience is a CRO offering translational oncology and immuno-oncology services, including preclinical models such as PDX, CDX, syngeneic models, GEMM, humanized mouse models, and organoid cultures. They also provide histopathology, genomics, and IC50 data services (per the firm's website).

What types of preclinical models does Crown Bioscience offer?

The firm offers over 600 PDX organoid models, over 1000 cancer cell lines, over 200 CDX models, and over 100 syngeneic and GEMM models. Models include in vitro and in vivo preparations, with some derived from HUB organoid protocols (per the firm's website).

Where are Crown Bioscience's facilities located?

Crown Bioscience has laboratory and office locations in San Diego, Frederick, and Kannapolis in the US; Loughborough in the UK; Leiden in the Netherlands; Hamburg in Germany; Beijing, Shanghai, Suzhou, and Taicang in China; Tokyo, Suwon, Hyderabad, and Singapore (per the firm's website).

How does Crown Bioscience support regulatory changes in animal testing?

The company references the FDA Modernization Act 2.0 and notes the FDA's planned phase-out of animal testing requirements for certain therapies. It positions its human-relevant in vitro models as alternatives to animal studies (per the firm's website).

Is Crown Bioscience a single family office or an asset manager?

No. Crown Bioscience is a contract research organization (CRO) — a scientific services company, not a family office or asset manager. It was not possible to confirm any investment or ownership structure from available primary sources.

Who are the primary decision-makers or owners at Crown Bioscience?

The available primary sources, including the firm's website, do not name any senior executives, board members, or owners. This information was not found in the consulted sources.

Does Crown Bioscience have a known AUM or investment portfolio?

No. Crown Bioscience does not report AUM, investment assets, or capital deployment. It is a CRO providing services, not an investment firm. The AUM band display is 'Undisclosed.'

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Santa Clara other profiles